Outcome of Senzimes rights issue
Uppsala, June 21, 2016. The subscription period for Senzime AB's new share issue with preferential rights for existing shareholders expired on 15 June 2016. The final outcome shows that the share issue was subscribed to 92.6 percent of the original offer. The remaining 7.5 percent of the shares is allocated to the underwriters. The proceeds in the issue totals approximately SEK 15.3 million before transaction costs.
“Senzime is entering a very exciting phase through the acquisition of Acacia and the completed rights issue. We now stand prepared for the commercialization phase, which is expected to begin late 2016. We are happy and proud of the interest that both existing and new shareholders have shown for Senzime. I would like to take the opportunity to thank everyone who has showed renewed confidence in us and at the same time extend a warm welcome to our new shareholders,” says Lena Söderström, CEO of Senzime.
“We are very pleased with the outcome of the issue, particularly given that 35% of the shareholders in Senzime were not able to participate in this specific issue, as they are US residents. Following the recent acquisition of Acacia, Senzime now offers a unique portfolio of solutions for patient monitoring; before, during and after surgery. We’re targeting a growing market with evident demands, which currently is valued at over 10 billion SEK in Europe and the US alone,” says Philip Siberg, chairman of Senzime.
The rights issue was subscribed for by shareholders through primary and secondary preferential rights at a total of 92.6 percent. In total, 2,037,498 shares, representing 50.7 percent of the shares offered, were subscribed for with subscription rights and 1,679,596 shares, representing 41.8 percent of the shares offered, were subscribed for without subscription rights. The remaining 298,067 shares, representing 7.5 percent of the shares offered will be allocated to underwriters in the issue. The rights issue is thereby fully subscribed for and the proceeds amount to approximately SEK 15.3 million before transaction costs.
Through the rights issue the share capital in Senzime increased by SEK 502 397.88. The total number of shares increased by 4,019,183 to 36,172,643.
Redeye AB acts as financial advisor and Advokatfirman Lindahl KB acts as legal adviser to Senzime in the rights issue. Aktieinvest FK AB acts as issuing institution in the rights issue.
The transaction costs are approximately SEK 2 million.
This is a translation of the Swedish original text.
For further information, please contact: Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: email@example.com
TO THE EDITORS
Senzime develops patient oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. In May 2016, Senzime broadened the scope and acquired Acacia Designs BV. The company's share is listed on Aktietorget, Stockholm. www.senzime.com
Acacia Designs is an international development company founded by leading clinicians and developers within the field of anesthesia. The company originates from research at Mayo Clinic, USA, the largest integrated non-commercial medical institution in the world and in 2015 ranked as the world's best hospital. Acacia has developed TetraGraph - a unique system for objective monitoring of patients undergoing anesthesia and the use of neuromuscular blocking agents (NMBAs). The system makes it possible to objectively determine the right dose of medication and when it is safe to wake the patient and allow for spontaneous breathing following surgery. Every year more than 20 million patients are affected by post-operative complications related to the use of NMBAs and premature extubation. The TetraGraph is intended to easily and precisely improve the monitoring of these patients to reduce complications and healthcare costs. Objective monitoring of patients receiving NMBAs is an established practice in several countries such as Scandinavia and France, and numbers of initiatives are underway to establish the method as Standard of Care. Acacia was founded in 2014 by Prof. Sorin J. Brull and Dr. David R. Hampton based on many years of research and development. www.acaciadesigns.eu